KEEPsAKE2 trial reveals potential of risankizumab for psoriatic arthritis
16 Jun 2021
bởiAudrey Abella
The humanized immunoglobulin G1 monoclonal antibody risankizumab led to significant improvements in patients with active psoriatic arthritis (PsA), including those with insufficient response or intolerance to one or two biologic therapies or to at least one DMARD*, according to the results of the phase III KEEPsAKE2 trial presented at EULAR 2021.